Bone marrow is a reservoir for CD4+CD25+ regulatory T cells that traffic through CXCL12/CXCR4 signals

被引:382
作者
Zou, LH [1 ]
Barnett, B [1 ]
Safah, H [1 ]
LaRussa, VF [1 ]
Evdemon-Hogan, M [1 ]
Mottram, P [1 ]
Wei, SN [1 ]
David, O [1 ]
Curiel, TJ [1 ]
Zou, WP [1 ]
机构
[1] Tulane Univ, Hlth Sci Ctr, Sect Hematol & Med Oncol, New Orleans, LA 70112 USA
关键词
D O I
10.1158/0008-5472.CAN-04-1987
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
CD4(+)CD25(+) regulatory T cells (Tregs) mediate peripheral T-cell homeostasis and contribute to self-tolerance. Their homeostatic and pathologic trafficking is poorly understood. Under homeostatic conditions, we show a relatively high prevalence of functional Tregs in human bone marrow. Bone marrow strongly expresses functional stromal-derived factor (CXCL12), the ligand for CXCR4. Human Tregs traffic to and are retained in bone marrow through CXCR4/CXCL12 signals as shown in chimeric nonobese diabetic/severe combined immunodeficient mice. Granulocyte colony-stimulating factor (G-CSF) reduces human bone marrow CXCL12 expression in vivo, associated with mobilization of marrow Tregs to peripheral blood in human volunteers. These findings show a mechanism for homeostatic Treg trafficking and indicate that bone marrow is a significant reservoir for Tregs. These data also suggest a novel mechanism explaining reduced acute graft-versus-host disease and improvement in autoimmune diseases following G-CSF treatment.
引用
收藏
页码:8451 / 8455
页数:5
相关论文
共 33 条
[1]
CD4+CD25high regulatory cells in human peripheral blood [J].
Baecher-Allan, C ;
Brown, JA ;
Freeman, GJ ;
Hafler, DA .
JOURNAL OF IMMUNOLOGY, 2001, 167 (03) :1245-1253
[2]
Role of the chemokine stromal cell-derived factor 1 in autoantibody production and nephritis in murine lupus [J].
Balabanian, K ;
Couderc, J ;
Bouchet-Delbos, L ;
Amara, A ;
Berrebi, D ;
Foussat, A ;
Baleux, FO ;
Portier, A ;
Durand-Gasselin, I ;
Coffman, RL ;
Galanaud, P ;
Peuchmaur, M ;
Emilie, D .
JOURNAL OF IMMUNOLOGY, 2003, 170 (06) :3392-3400
[3]
Quantification of estrogen receptor α and β expression in sporadic breast cancer [J].
Bièche, I ;
Parfait, B ;
Laurendeau, I ;
Girault, I ;
Vidaud, M ;
Lidereau, R .
ONCOGENE, 2001, 20 (56) :8109-8115
[4]
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival [J].
Curiel, TJ ;
Coukos, G ;
Zou, LH ;
Alvarez, X ;
Cheng, P ;
Mottram, P ;
Evdemon-Hogan, M ;
Conejo-Garcia, JR ;
Zhang, L ;
Burow, M ;
Zhu, Y ;
Wei, S ;
Kryczek, I ;
Daniel, B ;
Gordon, A ;
Myers, L ;
Lackner, A ;
Disis, ML ;
Knutson, KL ;
Chen, LP ;
Zou, WP .
NATURE MEDICINE, 2004, 10 (09) :942-949
[5]
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity [J].
Curiel, TJ ;
Wei, S ;
Dong, HD ;
Alvarez, X ;
Cheng, P ;
Mottram, P ;
Krzysiek, R ;
Knutson, KL ;
Daniel, B ;
Zimmermann, MC ;
David, O ;
Burow, M ;
Gordon, A ;
Dhurandhar, N ;
Myers, L ;
Berggren, R ;
Hemminki, A ;
Alvarez, RD ;
Emilie, D ;
Curiel, DT ;
Chen, LP ;
Zou, WP .
NATURE MEDICINE, 2003, 9 (05) :562-567
[6]
Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy [J].
Dhodapkar, MV ;
Krasovsky, J ;
Osman, K ;
Geller, MD .
JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 198 (11) :1753-1757
[7]
Ex vivo isolation and characterization of CD4+CD25+ T cells with regulatory properties from human blood [J].
Dieckmann, D ;
Plottner, H ;
Berchtold, S ;
Berger, T ;
Schuler, G .
JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 193 (11) :1303-1310
[8]
Bone marrow as a priming site for T-cell responses to blood-borne antigen [J].
Feuerer, M ;
Beckhove, P ;
Garbi, N ;
Mahnke, Y ;
Limmer, A ;
Hommel, M ;
Hämmerling, GJ ;
Kyewski, B ;
Hamann, A ;
Umansky, V ;
Schirrmacher, V .
NATURE MEDICINE, 2003, 9 (09) :1151-1157
[9]
Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow [J].
Feuerer, M ;
Beckhove, P ;
Bai, LH ;
Solomayer, EF ;
Bastert, G ;
Diel, IJ ;
Pedain, C ;
Oberniedermayr, M ;
Schirrmacher, V ;
Umansky, V .
NATURE MEDICINE, 2001, 7 (04) :452-458
[10]
FRANCOIS BJ, 2003, NAT REV IMMUNOL, V3, P189